Carna Biosciences, Inc. (TYO:4572)

Japan flag Japan · Delayed Price · Currency is JPY
300.00
-6.00 (-1.96%)
Aug 1, 2025, 3:30 PM JST
-1.96%
Market Cap5.97B
Revenue (ttm)598.71M
Net Income (ttm)-2.28B
Shares Out19.89M
EPS (ttm)-123.86
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume54,200
Average Volume114,830
Open306.00
Previous Close306.00
Day's Range300.00 - 309.00
52-Week Range220.00 - 482.00
Beta0.54
RSI43.66
Earnings DateAug 6, 2025

About Activision Blizzard

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, Luciferase PPI stable cell lines, kinase assay kits, peptide substrate, mobility shifty assay, and lipid kinase panels. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection assays. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable smal... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 63
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4572
Full Company Profile

Financial Performance

In 2024, Carna Biosciences's revenue was 636.00 million, a decrease of -60.86% compared to the previous year's 1.63 billion. Losses were -2.18 billion, 89.1% more than in 2023.

Financial Statements

News

There is no news available yet.